Halozyme Therapeutics
Update in progressHALO (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Halozyme Therapeutics, Inc. is a biopharmaceutical company that develops proprietary enzymes and related devices based on recombinant human hyaluronidase (rHuPH20) to enable subcutaneous administration of injectable biologics and other therapies. It markets Hylenex recombinant and XYOSTED, and collaborates with partners including Roche, Takeda, Pfizer, and AbbVie. Founded 1998, San Diego.
Company score
- Sentiment
- 0.46
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.02
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.23
- Governance
- 0.07
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.09
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.27
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEODr. Helen I. Torley M.B. Ch. B., M.R.C.P.
- Founded1998
- Employees423
- Websitehalozyme.com
Identifiers
- ISINUS40637H1095
- FIGIBBG000CZ8W54
- LEI529900242I3SV9AGM753
- CUSIP40637H109
- CIK0001159036